LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

enGene Therapeutics Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERENGN
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ENGN COVERAGE

What’s moving enGene Therapeutics Inc. now

Current reporting with the operating signal separated from the noise.

01
ENGNW enGene Therapeutics Inc. C/WTS 31/10/28 (TO PUR COM)

ENGNW enGene Therapeutics Inc. C/WTS 31/10/28 (TO PUR COM)

The story matters when it changes enGene Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
enGene Therapeutics Inc.

enGene Therapeutics Inc.

The story matters when it changes enGene Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

The story matters when it changes enGene Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript

The story matters when it changes enGene Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ENGN filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-06-15 · Period 2026-04-30SEC ↗10-QQuarterly financial reportFiled 2026-03-09 · Period 2026-01-31SEC ↗10-K/AAnnual financial reportFiled 2026-02-19 · Period 2025-10-31SEC ↗8-KMaterial company eventFiled 2026-07-17 · Period 2026-07-17SEC ↗8-KMaterial company eventFiled 2026-07-16 · Period 2026-07-15SEC ↗8-K/AMaterial company eventFiled 2026-06-18 · Period 2026-06-16SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-05-08 · Period 2026-06-09SEC ↗3Official SEC filingFiled 2026-07-22 · Period 2026-07-16SEC ↗
EARNINGS / QUARTERLY TRACKER

enGene Therapeutics Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.